Get started
Author

Gary Ian Sinclair

Development and validation of a self-completed HIV symptom index
2001 · A.C Justice, W Holmes, et al. · Journal of Clinical Epidemiology · 439
Clinical targeting of HIV capsid protein with a long-acting small molecule
2020 · John O. Link, Martin S. Rhee, et al. · Nature · 426
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
2022 · Sorana Segal-Maurer, Edwin DeJesus, et al. · New England Journal of Medicine · 324
PDF
Patient- and provider-reported adherence
2001 · J.H Wagner, A.C Justice, et al. · Journal of Clinical Epidemiology · 136
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial
2023 · Onyema Ogbuagu, Onyema Ogbuagu, et al. · The Lancet HIV · 73
Perspectives of people living with HIV‐1 on implementation of long‐acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation‐effectiveness study
2022 · Cindy P. Garris, Maggie Czarnogorski, et al. · Journal of the International AIDS Society · 49
PDF
Perspectives of healthcare providers on implementation of long‐acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation‐effectiveness study (CUSTOMIZE)
2022 · Maggie Czarnogorski, Cindy P. Garris, et al. · Journal of the International AIDS Society · 40
PDF
Role of microtubules in the cytoplasmic compartmentation of neurons
1987 · Peter W. Baas, Gary I. Sinclair, et al. · Brain Research · 30
Role of microtubules in the cytoplasmic compartmentation of neurons. II. Endocytosis in the growth cone and neurite shaft
1988 · Gary I. Sinclair, Peter W. Baas, et al. · Brain Research · 27
Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1
2025 · Amy E. Colson, Gordon E. Crofoot, et al. · Annals of Internal Medicine · 19
Mortality among HIV-1-infected women according to children's feeding modality - An individual patient data meta-analysis
2005 · François Dabis, Valériane Leroy, et al. · Ghent University Academic Bibliography (Ghent University) · 18
Clinical Outcomes and Perspectives of People With Human Immunodeficiency Virus Type 1 Twelve Months After Initiation of Long-acting Cabotegravir and Rilpivirine in an Observational Real-world US Study (BEYOND)
2025 · Dima Dandachi, Cindy Garris, et al. · Open Forum Infectious Diseases · 17
PDF
Hydroxyurea‐Induced Hepatitis in Human Immunodeficiency Virus‐‐Positive Patients
1999 · Sharon B. Weissman, Gary I. Sinclair, et al. · Clinical Infectious Diseases · 15
Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial
2026 · Jürgen K Rockstroh, Sheetal Kassim, et al. · The Lancet HIV · 10
577. Week 48 Results of a Phase 2 Study Evaluating Once-weekly Oral Islatravir Plus Lenacapavir
2025 · Amy E Colson, Gordon E Crofoot, et al. · Open Forum Infectious Diseases · 7
PDF
1607. Clinical Outcomes at Month 6 after Initiation of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) in an Observational Real-World Study (BEYOND)
2023 · Gary I Sinclair, Michael Sension, et al. · Open Forum Infectious Diseases · 7
PDF
1596. Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV: Week 104 Results
2023 · Onyema Ogbuagu, Edwin DeJesus, et al. · Open Forum Infectious Diseases · 6
PDF
Switch to single-tablet bictegravir–lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial
2026 · Chloe Orkin, Chloe Orkin, et al. · The Lancet · 5
Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial
2023 · Tahilin Sanchez Karver, Miguel Pascual-Bernaldez, et al. · AIDS Patient Care and STDs · 5
CARPA Standard Treatment Manual: a clinic manual for primary health care practitioners in remote and Indigenous health services in Central and Northern Australia
2014 · Sabina Knight, Andrew White, et al. · 5
Qualitative evaluation of survey questions to assess treatment preference for daily oral or long‑acting injectable antiretroviral therapy among people living with HIV
2024 · Cindy Garris, Irina Kolobova, et al. · PLoS ONE · 2
PDF
1288. US Healthcare Provider Perspectives on the initiation of cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world study (BEYOND)
2022 · Ricky K Hsu, John Phoenix, et al. · Open Forum Infectious Diseases · 2
Analytical treatment interruption as a tool in the evaluation of immune-mediated interventions for long-term antiretroviral-free control of HIV-1 among people with HIV
2025 · Ana Gabriela Pires dos Santos, Manal Abunimeh, et al. · Contemporary Clinical Trials · 1
1037. Qualitative Findings from a Hybrid III Implementation-Effectiveness Study to Explore Perspectives of Health-care Staff on Early Implementation of Cabotegravir and Rilpivirine Long Acting (CAB+RPV LA) Injectable HIV treatment in the US (CUSTOMIZE)
2020 · Maggie Czarnogorski, Cindy Garris, et al. · Open Forum Infectious Diseases · 1
PDF
Herpes virus infections.
2002 · Gary I. Sinclair, C. H. King, et al. · 1
Works count: 29
Citation count: 1,665
H-index: 13
I10-index: 14
Year
Topic
Type